Highly Potent SARS-CoV-2 Neutralization by Intravenous Immunoglobulins manufactured from Post-COVID-19 and COVID-19-Vaccinated Plasma Donations. (20th September 2021) - Karbiener, Michael
Abstract: From September 2020, some immunoglobulin lots from US plasma contained neutralizing antibodies against the newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Paralleled by the increasing numbers of post–coronavirus disease 2019 (COVID-19) donors, immunoglobulin lot antibody positivity increased to 93% by January 2021, at a mean titer of approximately 30 IU/mL. The correlation predicted that anti–SARS-CoV-2 potency would reach 345 IU/mL by July 2021. In addition to post–COVID-19 donors, the rapidly increasing number of plasma donors vaccinated against COVID-19 resulted in a mean antibody titer of >600 IU/mL in July 2021 immunoglobulin lots, with SARS-CoV-2 antibody titers for several lots even higher than those of earlier produced hyperimmune globulin products. Abstract : A rapidly increasing proportion of the US population, including plasma donors, now carries severe acute respiratory syndrome 2 (SARS-CoV-2) neutralizing antibodies, a consequence of earlier coronavirus disease 2019 (COVID-19) or—for many more—vaccination against it. The widely used messenger RNA vaccines induce higher antibody titers than COVID-19, and thus a proportion of immunoglobulin lots fractionated from US-origin plasma now contain SARS-CoV-2 neutralizing antibody titers even more potent than earlier produced COVID-19 hyperimmune globulin products.